Royalty Pharma Announces George Lloyd Is Named General Counsel

NEW YORK, Feb. 12, 2015 /PRNewswire/ -- Royalty Pharma is pleased to announce that George Lloyd has been named General Counsel of Royalty Pharma effective immediately. Since joining Royalty Pharma in 2011, Mr. Lloyd has been Executive Vice President Investments.

Mr. Lloyd joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. Previously, Mr. Lloyd was a partner at Goodwin Procter and Testa, Hurwitz & Thibeault in Boston, and an associate at Davis Polk & Wardwell in New York and Paris. From 2002 to 2003, Mr. Lloyd worked in Hong Kong as the chief financial officer and general counsel of the Asian operations of one of his clients. Mr. Lloyd received an A.B. from Princeton University and a J.D. from New York University Law School, where he was on the Law Review.

"Since joining Royalty Pharma in 2011, George has been a key player in the acquisition of over $6.5 billion in royalty assets as well as having significant responsibility for legal matters affecting Royalty Pharma. George's background makes him the ideal candidate to be Royalty Pharma's general counsel in addition to continuing his transactional role," said Pablo Legorreta, Founder & Chief Executive Officer of Royalty Pharma.

Separately, Royalty Pharma announced that Alex Kwit will become a Senior Adviser to Royalty Pharma. Mr. Kwit joined Royalty Pharma in 2001 and was previously an Executive Vice President of Royalty Pharma.

About Royalty Pharma
Royalty Pharma is the industry leader in the acquisition of revenue-producing intellectual property with over $12 billion in royalty assets principally royalty interests in leading pharmaceutical and biotechnology products. Royalty Pharma provides liquidity to holders of interests in revenue-producing intellectual property in approved biopharmaceutical products, and finances the clinical development of biopharmaceutical products in exchange for a royalty interest. Royalty Pharma owns royalty interests in 51 marketed and late stage biopharmaceutical products, including Abbott's Humira®, J&J's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Stribild®, Pfizer's Lyrica®, Merck's Januvia/Janumet®, Biogen Idec's Tecfidera®, Pharmacyclics' and J&J's Imbruvica®, Vertex's Kalydeco® and other cystic fibrosis products, Roche's Mircera®, and UCB's Cimzia®, among others. Additional company information is available at

Royalty Pharma | RP Management LLC
Investor Relations & Public Affairs
+ 1 (212) 883-0200
[email protected]

Logo -

To view the original version on PR Newswire, visit:

SOURCE Royalty Pharma

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.